In animal models and patients with pulmonary hypertension, PDE5 levels in the smooth muscle are elevated, leading to reduced cellular cGMP concentrations that causes abnormal regulation of vasodilatory mechanisms [6]. Here, PDE5A is linked to pulmonary arterial hypertension.